report-bg

Direct-Acting Antiviral Medicines Market

Segmentation by Drug Class Type (NS3/4A Protease Inhibitors, NS5A Polymerase Inhibitors, NS5B Polymerase Inhibitors, and Combination Drugs); and by End-User (Hospital Pharmacies, Retail Pharmacies, and Others) – Global Demand Analysis and Opportunity Outlook 2021-2029

Buy Now
Report ID: 3005 | Published On: Feb 13, 2023
Request Free Sample Copy

Market Segmentation

Our in-depth analysis of the direct-acting antiviral medicines market includes the following segments:

By Drug Class Type

  • NS3/4A protease inhibitors
  • NS5A Polymerase Inhibitors
  • NS5B Polymerase Inhibitors
  • Combination Drugs

By End-User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Growth Drivers

  • Increasing Prevalence of Liver Cirrhosis and Hepatocellular Carcinoma
  • Growing Investment in the Development of Advanced Therapies

Challenges

  • Low Access to Direct-Acting Antiviral Medicines in Low Economic Regions
  • Side Effects of Direct-Acting Antiviral Medicines


Direct-Acting-Antiviral-Medicines-Market
Get more information on this report: Request Sample PDF

Direct-Acting Antiviral Medicines Market Regional Synopsis

Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing hepatitis C infection prevalence and rising focus of major companies for expanding their product to countries in the region. Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to high awareness about direct-acting antiviral medicines in the region, accompanied by the presence of leading healthcare service providers in the region. Along with this, the North America also leads in terms of reimbursement policy system, which is also expected to contribute to the market growth in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the direct-acting antiviral medicines market on account of increase in number of patients with hepatitis C infection & lung cancer along with presence of large pharmaceutical companies. As per the analysis of World Health Organization, Europe is one of the most affected region by Hepatitis C infection, where approximately 14 million people are chronically infected with Hepatitis C, leading to about 112,500 deaths per year from Hepatitis C-related liver cancer and cirrhosis.

Direct-Acting-Antiviral-Medicines-Market-Share

The direct-acting antiviral medicines market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis


Direct-Acting-Antiviral-Medicines-Market-Share
Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Market

    • AbbVie, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Janssen Therapeutics
    • Bristol-Myers Squibb
    • Merck & Co.
    • Vertex Pharmaceuticals
    • Johnson & Johnson
    • Gilead Sciences, Inc.
    • Natco Pharma
    • Dr. Reddy’s Laboratories

     

     


In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the direct-acting antiviral medicines market?

Ans: Increasing prevalence of liver cirrhosis and hepatocellular carcinoma and the growing investment in the development of advanced therapies are the key factors driving market growth.

2) What would be the CAGR of direct-acting antiviral medicines market over the forecast period?

Ans: The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.

3) What are the challenges affecting the direct-acting antiviral medicines market growth?

Ans: Low access to direct-acting antiviral medicines in low economic regions and side effects of direct-acting antiviral medicines are estimated to hamper market growth.

4) Which region will provide more business opportunities for growth of direct-acting antiviral medicines market in future?

Ans: The market in Asia Pacific region will provide ample growth opportunities owing to the increasing hepatitis C infection prevalence and rising focus of major companies for expanding their product to countries in the region.

5) Who are the major players dominating the direct-acting antiviral medicines market?

Ans: The major players dominating the direct-acting antiviral medicines market are AbbVie, Inc., Janssen Therapeutics, Bristol-Myers Squibb, and Merck & Co. among others.

6) How are the company profiles selected?

Ans: The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the direct-acting antiviral medicines market?

Ans: The market is segmented by drug class type, end-user and region.

8) Which segment under the end-user segment captures the largest market size in the direct-acting antiviral medicines market?

Ans: With respect to end-user, the hospital pharmacies segment is anticipated to hold the largest market share owing to the growing preference among individuals for choosing hospitals as their treatment option and there is an increased availability of prescribed antiviral medicines at hospital pharmacies.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample